LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 34

Suchoptionen

  1. Artikel ; Online: Gamma-Ray Spectrometry for the Measurement of Mass Attenuation Coefficient and Bulk Density of Soil: A Review

    Dhingra, Nitish

    Communications in Soil Science and Plant Analysis. 2023 Sept. 25, v. 54, no. 17 p.2329-2335

    2023  

    Abstract: The gamma-ray mass attenuation coefficient is a crucial parameter to characterize the penetration and propagation of gamma rays in complex, multiphased, and heterogeneous materials like soil. Microscopically, soils contain minerals, water, gases, and ... ...

    Abstract The gamma-ray mass attenuation coefficient is a crucial parameter to characterize the penetration and propagation of gamma rays in complex, multiphased, and heterogeneous materials like soil. Microscopically, soils contain minerals, water, gases, and other fluids that influence gamma-ray transmission. This paper discusses the potential of the Gamma Ray Spectroscopy (GRS) technique for precise measurement of various soil properties, focusing on soil’s mass attenuation coefficient and bulk density. The limitations and advantages of GRS over conventional methods are also highlighted.
    Schlagwörter bulk density ; gamma radiation ; plant analysis ; soil ; spectroscopy ; gamma-ray spectrometry ; mass attenuation coefficient
    Sprache Englisch
    Erscheinungsverlauf 2023-0925
    Umfang p. 2329-2335.
    Erscheinungsort Taylor & Francis
    Dokumenttyp Artikel ; Online
    ZDB-ID 419718-5
    ISSN 1532-2416 ; 0010-3624
    ISSN (online) 1532-2416
    ISSN 0010-3624
    DOI 10.1080/00103624.2023.2223650
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Obesity/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials.

    Verma, Raj / Dhingra, Nitish K / Connelly, Kim A

    Current opinion in cardiology

    2024  Band 39, Heft 2, Seite(n) 92–97

    Abstract: Purpose of review: Heart failure with preserved ejection fraction (HFpEF) is a leading and growing cause of morbidity and mortality globally. Of the various phenotypes identified, the obesity (or cardiometabolic) phenotype appears to be most common. The ...

    Abstract Purpose of review: Heart failure with preserved ejection fraction (HFpEF) is a leading and growing cause of morbidity and mortality globally. Of the various phenotypes identified, the obesity (or cardiometabolic) phenotype appears to be most common. The purpose of this review is to provide the clinician with an abridged understanding of recent developments that have elucidated obesity/visceral adiposity as a central mechanism linking inflammation/immune dysregulation to the development of the HFpEF syndrome. Recent clinical trials examining the efficacy of pharmacological treatments that target obesity in HFpEF will also be discussed.
    Recent findings: Recent data indicate that visceral adiposity and insulin resistance in HFpEF serve as key mechanisms driving inflammation and immune dysregulation, which play a critical role in the development of cardiac stiffness, diastolic dysfunction and fibrosis in HFpEF. In obesity, alterations in macrophage polarization, changes in innate and adaptive immune systems and altered myocardial energetics promote metabolic inflammation in HFpEF. Finally, emerging data suggest that inflammatory biomarkers, specifically, IL-6, may provide useful information about HFpEF severity and symptom burden in obesity.
    Summary: The obesity phenotype of HFpEF is seen in upward of 80% with HFpEF. Obesity is not just a bystander, but plays an essential role in the pathobiology and clinical course of HFpEF. Targeting overweight/obesity in HFpEF with GLP-1 receptor agonists holds promise in these patients.
    Mesh-Begriff(e) Humans ; Heart Failure ; Stroke Volume/physiology ; Obesity/complications ; Phenotype ; Inflammation
    Sprache Englisch
    Erscheinungsdatum 2024-01-25
    Erscheinungsland United States
    Dokumenttyp Review ; Journal Article
    ZDB-ID 645186-x
    ISSN 1531-7080 ; 0268-4705
    ISSN (online) 1531-7080
    ISSN 0268-4705
    DOI 10.1097/HCO.0000000000001113
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Chronic heart failure management in adult patients with congenital heart disease.

    Dhingra, Nitish K / Mazer, C David / Connelly, Kim A / Verma, Subodh

    Current opinion in cardiology

    2023  Band 38, Heft 2, Seite(n) 82–87

    Abstract: Purpose of review: A growing number of adult patients with congenital heart disease (ACHD) are entering the healthcare system as a result of advances in the diagnosis and management of congenital heart defects. Heart failure is a common final pathway ... ...

    Abstract Purpose of review: A growing number of adult patients with congenital heart disease (ACHD) are entering the healthcare system as a result of advances in the diagnosis and management of congenital heart defects. Heart failure is a common final pathway for this diverse patient population, representing the leading cause of mortality in ACHD patients. Herein, we review present guideline-directed management of heart failure in ACHD patients.
    Recent findings: There exists a dearth of data to guide management of ACHD-related heart failure. Given this gap, recent guidelines have been limited in the recommendations they can provide for this patient population, with practitioners being consequently forced to generalize findings from studies of acquired heart disease patients based on mechanistic plausibility. The small number of studies directly assessing ACHD patients have been largely limited in their clinical relevance through being negative, small, observational, limited to specific subsets of ACHD patients or assessing nonvalidated outcomes.
    Summary: Despite the prevalence and impact of ACHD-related heart failure, there are limited evidence-based therapies for its management. Given the rising burden of this clinical problem, definitive trials assessing newer therapies are required to establish their potential role in heart failure amongst ACHD patients.
    Mesh-Begriff(e) Humans ; Adult ; Heart Defects, Congenital/complications ; Heart Defects, Congenital/therapy ; Heart Defects, Congenital/diagnosis ; Heart Failure/diagnosis ; Heart Failure/epidemiology ; Heart Failure/therapy
    Sprache Englisch
    Erscheinungsdatum 2023-01-19
    Erscheinungsland United States
    Dokumenttyp Review ; Journal Article
    ZDB-ID 645186-x
    ISSN 1531-7080 ; 0268-4705
    ISSN (online) 1531-7080
    ISSN 0268-4705
    DOI 10.1097/HCO.0000000000001011
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.

    Verma, Atul / Dhingra, Nitish / Yanagawa, Bobby

    The New England journal of medicine

    2021  Band 384, Heft 10, Seite(n) 973–974

    Mesh-Begriff(e) Anticoagulants/adverse effects ; Atrial Fibrillation/drug therapy ; Humans ; Mitral Valve/diagnostic imaging ; Mitral Valve/surgery ; Rivaroxaban/therapeutic use ; Warfarin
    Chemische Substanzen Anticoagulants ; Warfarin (5Q7ZVV76EI) ; Rivaroxaban (9NDF7JZ4M3)
    Sprache Englisch
    Erscheinungsdatum 2021-03-11
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2035891
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Cardiopulmonary bypass and cardiac surgery associated pulmonary hypertension: The need for proactivity and reactivity.

    Hibino, Makoto / Dhingra, Nitish K / Verma, Raj / Yanagawa, Bobby

    Journal of cardiac surgery

    2022  

    Abstract: Pulmonary hypertension remains an important postcardiac surgical problem requiring prompt identification and management. In this edition of the Journal of Cardiac Surgery, Fayad and colleagues provide a detailed review of this topic, including ... ...

    Abstract Pulmonary hypertension remains an important postcardiac surgical problem requiring prompt identification and management. In this edition of the Journal of Cardiac Surgery, Fayad and colleagues provide a detailed review of this topic, including epidemiology, mechanistic underpinnings, and available treatment options. In addition to responding to postoperative pulmonary hypertension, however, proactive measures including optimal timing of intervention are paramount to preventing the development of pulmonary hypertension and its associated complications.
    Sprache Englisch
    Erscheinungsdatum 2022-11-15
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 639059-6
    ISSN 1540-8191 ; 0886-0440
    ISSN (online) 1540-8191
    ISSN 0886-0440
    DOI 10.1111/jocs.17161
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Increased patency with comparable mortality and revascularization risk: Is the case for no-touch vein harvesting open and shut?

    Hibino, Makoto / Dhingra, Nitish K / Verma, Subodh

    Journal of cardiac surgery

    2021  Band 36, Heft 11, Seite(n) 4376–4377

    Mesh-Begriff(e) Endoscopy ; Humans ; Saphenous Vein ; Tissue and Organ Harvesting ; Treatment Outcome ; Vascular Patency
    Sprache Englisch
    Erscheinungsdatum 2021-09-03
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 639059-6
    ISSN 1540-8191 ; 0886-0440
    ISSN (online) 1540-8191
    ISSN 0886-0440
    DOI 10.1111/jocs.15973
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Aortic valve neocuspidization and its technical nuance.

    Dhingra, Nitish K / Verma, Subodh / Yanagawa, Bobby / Hibino, Makoto

    Journal of cardiac surgery

    2022  Band 37, Heft 8, Seite(n) 2475–2476

    Abstract: Aortic valve neocuspidization or Ozaki procedure represents an advanced surgical strategy for the management of patients with aortic valvulopathy. It has been shown to have clinical and hemodynamic outcomes that compare favorably with aortic valve ... ...

    Abstract Aortic valve neocuspidization or Ozaki procedure represents an advanced surgical strategy for the management of patients with aortic valvulopathy. It has been shown to have clinical and hemodynamic outcomes that compare favorably with aortic valve replacement as it restores physiological aortic valve function and left ventricular remodeling. There are, however, a new set of issues including structural valve deterioration, leaflet tear/perforation, and need for reoperation. A keen understanding of the technical nuances involved with the Ozaki procedure may help in reducing the incidence of such adverse outcomes.
    Mesh-Begriff(e) Aortic Valve/surgery ; Aortic Valve Insufficiency/surgery ; Aortic Valve Stenosis/surgery ; Heart Valve Diseases ; Heart Valve Prosthesis ; Heart Valve Prosthesis Implantation/methods ; Humans ; Reoperation ; Treatment Outcome
    Sprache Englisch
    Erscheinungsdatum 2022-05-09
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 639059-6
    ISSN 1540-8191 ; 0886-0440
    ISSN (online) 1540-8191
    ISSN 0886-0440
    DOI 10.1111/jocs.16604
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Complete transcatheter versus complete surgical management for combined aortic stenosis and coronary artery disease: A false dichotomy?

    Dhingra, Nitish K / Verma, Subodh / Yanagawa, Bobby / Hibino, Makoto

    Journal of cardiac surgery

    2022  Band 37, Heft 7, Seite(n) 2084–2085

    Abstract: Coronary artery disease and aortic stenosis often occur concomitantly owing to their shared risk factor profile. While standard management of these patients has been through surgical methods including surgical aortic valve replacement and coronary artery ...

    Abstract Coronary artery disease and aortic stenosis often occur concomitantly owing to their shared risk factor profile. While standard management of these patients has been through surgical methods including surgical aortic valve replacement and coronary artery bypass grafting, recent studies have investigated the potential role of complete transcatheter management (i.e., transcatheter aortic valve implantation and percutaneous coronary intervention) for these patients. In this editorial, we discuss the growing body of evidence suggesting long-term risks of transcatheter interventions despite their short-term benefits and also look to the future of hybrid approaches for multifaceted structural heart pathologies.
    Mesh-Begriff(e) Aortic Valve/surgery ; Aortic Valve Stenosis/complications ; Aortic Valve Stenosis/surgery ; Coronary Artery Disease/complications ; Coronary Artery Disease/surgery ; Humans ; Percutaneous Coronary Intervention/methods ; Transcatheter Aortic Valve Replacement/methods ; Treatment Outcome
    Sprache Englisch
    Erscheinungsdatum 2022-04-17
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 639059-6
    ISSN 1540-8191 ; 0886-0440
    ISSN (online) 1540-8191
    ISSN 0886-0440
    DOI 10.1111/jocs.16531
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure.

    Verma, Subodh / Dhingra, Nitish K / Pandey, Arjun K / Cosentino, Francesco

    European heart journal

    2022  Band 43, Heft 31, Seite(n) 2994–2996

    Mesh-Begriff(e) Benzhydryl Compounds ; Glucosides ; Heart Failure/drug therapy ; Humans ; Hyperkalemia/chemically induced ; Potassium ; Sodium-Glucose Transporter 2 Inhibitors/pharmacology ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
    Chemische Substanzen Benzhydryl Compounds ; Glucosides ; Sodium-Glucose Transporter 2 Inhibitors ; empagliflozin (HDC1R2M35U) ; Potassium (RWP5GA015D)
    Sprache Englisch
    Erscheinungsdatum 2022-06-06
    Erscheinungsland England
    Dokumenttyp Editorial ; Comment
    ZDB-ID 603098-1
    ISSN 1522-9645 ; 0195-668X
    ISSN (online) 1522-9645
    ISSN 0195-668X
    DOI 10.1093/eurheartj/ehac304
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.

    Pandey, Arjun K / Dhingra, Nitish K / Hibino, Makoto / Gupta, Vijay / Verma, Subodh

    ESC heart failure

    2022  Band 9, Heft 2, Seite(n) 942–946

    Abstract: Aims: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to be an effective therapy in improving heart failure outcomes. We conducted a meta-analysis of randomized controlled trials to evaluate the efficacy of SGLT2 inhibitors in heart ... ...

    Abstract Aims: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to be an effective therapy in improving heart failure outcomes. We conducted a meta-analysis of randomized controlled trials to evaluate the efficacy of SGLT2 inhibitors in heart failure patients with either a reduced or preserved ejection fraction.
    Methods and results: We searched MEDLINE and EMBASE for large (≥1000 patients) randomized controlled trials evaluating the effects of SGLT2 inhibitors compared with placebo in the setting of heart failure until September 2021. Our primary outcome was the composite of heart failure hospitalization and cardiovascular death, and secondary outcomes included all-cause mortality and total heart failure hospitalizations. We pooled hazard ratios and risk ratios and evaluated risk of bias with the Cochrane Collaboration tool. Four randomized controlled trials (DAPA HF, EMPEROR-Preserved, EMPEROR-Reduced, and SOLOIST-WHF) were included (n = 15 684); two of which evaluated patients with a reduced LVEF, one of which evaluated patients with a preserved LVEF, and one of which included both. Treatment with SGLT2 inhibitors resulted in a significant reduction in the composite of CV death and heart failure hospitalization (HR: 0.76, 95% CI: 0.70, 0.82, I
    Conclusions: Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular death and heart failure hospitalization among patients with heart failure, regardless of LVEF status.
    Mesh-Begriff(e) Diabetes Mellitus, Type 2/complications ; Glucose ; Heart Failure/complications ; Heart Failure/drug therapy ; Humans ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
    Chemische Substanzen Sodium-Glucose Transporter 2 Inhibitors ; Sodium (9NEZ333N27) ; Glucose (IY9XDZ35W2)
    Sprache Englisch
    Erscheinungsdatum 2022-02-02
    Erscheinungsland England
    Dokumenttyp Journal Article ; Meta-Analysis
    ZDB-ID 2814355-3
    ISSN 2055-5822 ; 2055-5822
    ISSN (online) 2055-5822
    ISSN 2055-5822
    DOI 10.1002/ehf2.13805
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang